Clinical Trial Update: Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the combination of clarithromycin and rifabutin for Mycobacterium avium complex lung disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycobacterium Avium Complex Lung Disease

Drugs mentioned

• RIFABUTIN (Rifabutin)
• clarithromycin (clarithromycin)

Snippet

Sponsor: The University of Texas Health Science Center at Tyler | Conditions: Mycobacterium Avium Complex Lung Disease | Phase 4 | Status: COMPLETED